Lexi-Comp

Lexi-Comp's transactional drug data and reference solutions can help your EMR comply with the final rule on Meaningful Use by helping you support the technical capabilities required for certification of your system. Specifically, we can provide your EMR the core drug data and reference information you need to achieve the clinical decision support component of Meaningful Use. When integrated into your system, Lexi-Comp will:

•        Provide data for drug-drug, drug-disease and drug-allergy interaction screening
•        Provide duplicate therapy and dose range checking for pediatric and adult patients
•        Provide a drug list of dispensable products with mapping to NDC numbers, RXCUI, Lexi-Comp’s Global ID, and Multum DNUM and generic product codes
•       Support the maintenance of active medication and allergy lists within an EMR
•      Promote interoperability
•     Allow users to generate patient-specific education leaflets

170.207 (d) Vocabulary Standards for Representing Electronic Health Information

·         Lexi-Data uses RXCUI codes from RXNorm on medications

170.302 (m) Patient Specific Education Resources

·         Lexi-Comp Online can provide patient tailored educational information pertaining to their medications, conditions or procedures.

170.302 General Certification Criteria for Complete EHRs or EHR modules

·         Lexi-Data provides medication lists for provider order entry

·         Lexi-Data supports drug-drug and drug-allergy interaction checking

·         Lexi-Data facilitates the maintenance of the active medication list as well as the allergy list

·         Lexi-Comp Online provides numerous calculators, including one to calculate the Body Mass Index based on a patient’s height and weight

·         Lexi-Data can be integral to customized clinical decision support rules designed around medications

170.304 Specific Certification Criteria for Complete EHRs or EHR Modules Designed for an Ambulatory Setting

·         Lexi-Data supports the requirement to generate an electronic copy of health information pertaining to the patient’s medication and allergy lists.

·         Lexi-Data facilitates the selection of medications for e-prescribing activities

As with renal impairment, the threshold at which an adjustment of dosage may be necessary depends not only on the route of elimination, but the mechanisms involved. These dosage precautions are essential. Drug classifications rarely point out differences between members regarding the pathways of metabolism. Hepatic metabolism is complex, but it can generally be broadly grouped into two broad types of reactions/pathways: Phase I and Phase II reactions.

Phase I reactions include reactions which greatly modify the chemical structure of the drug. In a way, these are more difficult reactions to perform. The ability of the liver to carry out these functions can be significantly decreased at moderate levels of functional impairment. Phase II reactions are in many ways “simpler” from a chemical standpoint, and the ability to perform them can be preserved even in significant hepatic damage. For this reason, it is important to know not only whether a drug is metabolized, but also the type of metabolism. In this way a therapeutic dosage may be determined.

The Medicare and Medicaid EHR incentive programs provide a financial reward for the meaningful use of EHRs to achieve health and efficiency goals. By implementing and meaningfully using an EHR system, providers will reap benefits beyond financial incentives - like reduction in errors, availability of records and data, reminders and alerts, clinical decision support and e-Prescribing/refill automation.

To qualify for incentive payments, meaningful use requirements must be met in the following ways:

• Medicare EHR incentive program - Eligible professionals and hospitals must successfully demonstrate meaningful use of certified electronic health record technology every year they participate in the program.

• Medicaid EHR incentive program - Eligible professionals and hospitals may qualify for incentive payments for the adoption, implementation, upgrade or the demonstration of meaningful use in their first year of participation. They must successfully demonstrate meaningful use for the remaining years they participate in the program.